STOCKHOLM, Sweden I March 11,2013 I Moberg Derma AB (STO:MOB) has decided to discontinue the development of Limtop – a drug candidate for the treatment of actinic keratosis. The decision is based on data from a completed phase II clinical trial, where the efficacy of Limtop did not reach the predefined target.
"Based on data from the completed study, we deem that the project’s commercial potential has decreased and that continued investment therefore is not justified. This does not affect the company’s assessment for continued profitable growth during 2013," said Peter Wolpert, President and CEO of Moberg Derma AB.
About this information Moberg Derma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 AM (CET) on March 11, 2013.
About Moberg Derma
Moberg Derma AB (publ) is a rapidly growing Swedish pharmaceutical company with direct sales through its own sales organization in the US and sales through distributors in more than 35 countries. The company’s product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal®, Jointflex®, Emtrix® and Kaprolac®. Emtrix® (Nalox™ in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Derma has offices in Stockholm and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergderma.com.
SOURCE: Moberg Derma
Post Views: 126
STOCKHOLM, Sweden I March 11,2013 I Moberg Derma AB (STO:MOB) has decided to discontinue the development of Limtop – a drug candidate for the treatment of actinic keratosis. The decision is based on data from a completed phase II clinical trial, where the efficacy of Limtop did not reach the predefined target.
"Based on data from the completed study, we deem that the project’s commercial potential has decreased and that continued investment therefore is not justified. This does not affect the company’s assessment for continued profitable growth during 2013," said Peter Wolpert, President and CEO of Moberg Derma AB.
About this information Moberg Derma discloses this information pursuant to the Swedish Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 8.30 AM (CET) on March 11, 2013.
About Moberg Derma
Moberg Derma AB (publ) is a rapidly growing Swedish pharmaceutical company with direct sales through its own sales organization in the US and sales through distributors in more than 35 countries. The company’s product portfolio includes topical products for the treatment of skin disorders and pain under the brands Kerasal®, Jointflex®, Emtrix® and Kaprolac®. Emtrix® (Nalox™ in many markets) is the leading product for the treatment of nail disorders in the Nordic market. The portfolio is developed further through acquisitions and in-licensing of products as well as product development with focus on innovative drug delivery based on proven compounds. Moberg Derma has offices in Stockholm and New Jersey and the company’s share (OMX: MOB) is listed on the Small Cap list of the NASDAQ OMX Nordic Exchange Stockholm. For further information, please visit: www.mobergderma.com.
SOURCE: Moberg Derma
Post Views: 126
